Results on triple combination (A+V+O) for hig... - CLL Support

CLL Support

22,367 members38,474 posts

Results on triple combination (A+V+O) for high risk patients -with-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-cll

spi3 profile image
spi3
7 Replies

The Bottom Line:

In this ongoing trial, the triple combination therapy using acalabrutinib, venetoclax, and obinutuzumab is highly active. Thus far this drug combination has produced durable remissions as a frontline treatment in patients with TP53 mutation CLL and has been generally well tolerated, with a low 2.9% incidence of atrial fibrillation and zero of the more serious abnormal ventricular heart irregularities -

See report at

cllsociety.org/2023/01/ash-...

Written by
spi3 profile image
spi3
To view profiles and participate in discussions please or .
Read more about...
7 Replies
LeoPa profile image
LeoPa

What is the out of pocket cost? $50,000 a month?

spi3 profile image
spi3 in reply to LeoPa

I'm not sure - my husband is in a Dana-Faber study - our health insurance pays for all scans, visit co-pays, blood tests...the study just pays for the medicine(s).

LeoPa profile image
LeoPa in reply to spi3

Oh my, I forgot the other costs. The meds alone must be 50K a month.

Smakwater profile image
Smakwater

Sounds encouraging spi3,

JM

spi3 profile image
spi3 in reply to Smakwater

it is and we get to see Dr Davis in two weeks so I can ask him about his findings. I'm so glad they have the studies and are generating more treatments - I'm hoping and praying they will eradicate CLL and all types of cancers too (in the next 5 years).....

Smakwater profile image
Smakwater

Yes, it would be so nice to put and end to the fear and suffering.

Thank You for sharing the hope.

All the best to you on this treatment path!

spi3 profile image
spi3 in reply to Smakwater

Praying g the best for you too

You may also like...

Encouraging results from venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen

good response to a second venetoclax treatment, from a trial of 46 CLL patients who relapsed after...

ASH 2017: Dr. Richard Furman on the importance of MCL-1 in CLL (chronic lymphocytic leukemia)

already aware!). From the CLL Society website: As good as venetoclax is as a single agent, there...

Health Canada approves Ibrutinib plus Rituximab for First Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

ximab-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia-cll--834973397.html Now it's...

FDA Frontline Approval of Venetoclax and Obinituzumab in the USA

ntreated-chronic-lymphocytic-leukemia-cll-or-small-lymphocytic-lymphoma-sll/ This is a big deal....

Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE)

Jeff P Sharman, Mato et al Patients with chronic lymphocytic leukaemia and high-risk features...